Efficacy of the sustained-release hydromorphone in neuropathic pain management: Pooled analysis of three open-label studies

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 24, Issue 3, 2010, Pages 200-212

  Moulin, Dwight E ^a   Richarz, Ute ^b   Wallace, Mark ^c   Jacobs, Adam ^d   Thipphawong, John ^d  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b Univerisity of California at San Diego Center for Pain Medicine ^*

^c UNIVERSITY OF CALIFORNIA   (United States)

^d M4 2A   (United States)

Author keywords

Analgesia; Chronic pain; Hydromorphone; Low back pain; Neuropathic pain; Opioid; Pooled analysis

Indexed keywords

HYDROMORPHONE; OROS; UNCLASSIFIED DRUG;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SOMNOLENCE; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 77955861750     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2010.502213     Document Type: Article

References (28)

1. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle: IASP Press. 1994;212.
2. Shipton EA, Tait B. Flagging the pain: preventing the burden of chronic pain by identifying and treating risk factors in acute pain. Eur J Anaesthesiol. 2005;22:405-412.
3. The Neuropathic Pain Network. Available at: http://www. neuropathicpainnetwork.org/english/index.asp. Accessed 20 January 2010
4. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
6. Chaplan SR, Duncan SR, Brodsky JB, Brose WG. Morphine and hydromorphone epidural analgesia. A prospective, randomized comparison. Anesthesiology. 1992;77:1090-1094.
7. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22-S32.
8. Eisenberg E, McNicol ED, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;(3):CD006146. DOI: 10.1002/14651858.CD006146.
9. Arńer S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11-23.
10. Goodarzi M. Comparison of epidural morphine, hydromorphone and fentanyl for postoperative pain control in children undergoing orthopaedic surgery. Paediatr Anaesth. 1999;9: 419-422.
11. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002;(1):CD003447.
12. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84-96.
13. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223-1232.
14. Gupta S, Sathyan G. Providing constant analgesia with OROS hydromorphone. J Pain Symptom Manage. 2007;33(2 Suppl):S19-S24.
15. Turgeon J, Gröning R, Sathyan G, Thipphawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv. 2010;7:137-144.
16. Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS R- ). A retrospective study. Drug Saf. 2002;25:1021-1033.
17. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronicmalignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355-368.
18. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to oncedaily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2008;36:343-352.
19. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract. 2007;61:1671-1676.
20. Wallace M, Skowronski R, Khanna S, et al. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin. 2007;23:P1-P9.
21. Hanna M, Thipphawong J; 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.
22. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29:874-888.
23. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29:401-410. (Pubitemid 40602521)
24. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210.
25. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20:309-318.
26. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
27. Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manage. 2009;5:97-105.
28. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.